A3 adenosine receptor: pharmacology and role in disease
- PMID: 19639286
- DOI: 10.1007/978-3-540-89615-9_10
A3 adenosine receptor: pharmacology and role in disease
Abstract
The study of the A(3) adenosine receptor (A(3)AR) represents a rapidly growing and intense area of research in the adenosine field. The present chapter will provide an overview of the expression patterns, molecular pharmacology and functional role of this A(3)AR subtype under pathophysiological conditions. Through studies utilizing selective A(3)AR agonists and antagonists, or A(3)AR knockout mice, it is now clear that this receptor plays a critical role in the modulation of ischemic diseases as well as in inflammatory and autoimmune pathologies. Therefore, the potential therapeutic use of agonists and antagonists will also be described. The discussion will principally address the use of such compounds in the treatment of brain and heart ischemia, asthma, sepsis and glaucoma. The final part concentrates on the molecular basis of A(3)ARs in autoimmune diseases such as rheumatoid arthritis, and includes a description of clinical trials with the selective agonist CF101. Based on this chapter, it is evident that continued research to discover agonists and antagonists for the A(3)AR subtype is warranted.
Similar articles
-
The A3 adenosine receptor: an enigmatic player in cell biology.Pharmacol Ther. 2008 Jan;117(1):123-40. doi: 10.1016/j.pharmthera.2007.09.002. Epub 2007 Sep 22. Pharmacol Ther. 2008. PMID: 18029023 Review.
-
Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.Expert Opin Ther Pat. 2012 Apr;22(4):369-90. doi: 10.1517/13543776.2012.669375. Epub 2012 Mar 22. Expert Opin Ther Pat. 2012. PMID: 22435652 Review.
-
A3 adenosine receptor-mediated protection of the ischemic heart.Vascul Pharmacol. 2005 Apr-May;42(5-6):271-9. doi: 10.1016/j.vph.2005.02.009. Epub 2005 Apr 19. Vascul Pharmacol. 2005. PMID: 15922260 Review.
-
A1 adenosine receptor antagonists, agonists, and allosteric enhancers.Handb Exp Pharmacol. 2009;(193):25-58. doi: 10.1007/978-3-540-89615-9_2. Handb Exp Pharmacol. 2009. PMID: 19639278 Review.
-
The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Med Res Rev. 2013 Mar;33(2):235-335. doi: 10.1002/med.20254. Epub 2011 Nov 16. Med Res Rev. 2013. PMID: 22095687 Review.
Cited by
-
The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells.PLoS One. 2012;7(6):e39317. doi: 10.1371/journal.pone.0039317. Epub 2012 Jun 25. PLoS One. 2012. PMID: 22761760 Free PMC article.
-
Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.Curr Cardiol Rev. 2016;12(1):18-26. doi: 10.2174/1573403x12666160111125116. Curr Cardiol Rev. 2016. PMID: 26750723 Free PMC article. Review.
-
An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway.Sci Rep. 2015 Mar 12;5:9047. doi: 10.1038/srep09047. Sci Rep. 2015. PMID: 25762375 Free PMC article.
-
Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.Pharmacol Ther. 2022 Dec;240:108300. doi: 10.1016/j.pharmthera.2022.108300. Epub 2022 Oct 22. Pharmacol Ther. 2022. PMID: 36283452 Free PMC article. Review.
-
Effect of HEMADO on Level of CK-MB and LDH Enzymes after Ischemia/Reperfusion Injury in Isolated Rat Heart.Bioimpacts. 2013;3(2):101-4. doi: 10.5681/bi.2013.003. Epub 2012 Nov 13. Bioimpacts. 2013. PMID: 23878794 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials